New Agents and Evolving Strategies in Prostate Cancer: Focus on Castration-Sensitive Disease

Download All
Learn how experts select and carefully consider the toxicity profiles of established and newly emerging androgen-deprivation therapies toward the optimal management of patients with castration-sensitive prostate cancer. Download slides from the live symposium and read an expert-authored commentary on androgen-deprivation therapies for castration-sensitive prostate cancer.
Atish Choudhury, MD, PhD

ClinicalThought

Expert commentary by Atish Choudhury, MD, PhD, on key takeaways from a live symposium on new and evolving androgen-deprivation therapies and treatment approaches for patients with castration-sensitive prostate cancer, including data from the 2022 ASCO Genitourinary Cancers Symposium.

Atish Choudhury, MD, PhD Released: March 30, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Myovant Sciences, Inc.
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings